Cargando…

Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells

Thyroid cancer is the most common endocrine malignancy. A multitargeted tyrosine kinase inhibitor, lenvatinib, has been used for the treatment of advanced thyroid cancer. To elucidate the mechanism of resistance to lenvatinib in thyroid cancer cells, we established lenvatinib‐resistant sublines and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohno, Koichi, Shibata, Tomohiro, Ito, Ken‐ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459297/ https://www.ncbi.nlm.nih.gov/pubmed/35723021 http://dx.doi.org/10.1111/cas.15465

Ejemplares similares

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
por: Nakagawa, Takayuki, et al.
Publicado: (2014)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
por: Tateai, Yoshikazu, et al.
Publicado: (2023)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior
por: Revilla, Giovanna, et al.
Publicado: (2023)

The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
por: Ono, Mayu, et al.
Publicado: (2021)

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
por: Guo, Yuchen, et al.
Publicado: (2022)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
por: Sobani, Zain A, et al.
Publicado: (2016)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer
por: Shibutani, Yuma, et al.
Publicado: (2023)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
por: Watanabe, Takayuki, et al.
Publicado: (2021)

Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
por: Masaki, Chie, et al.
Publicado: (2021)

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature
por: Shibata, Osamu, et al.
Publicado: (2020)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
por: Takahashi, Shunji, et al.
Publicado: (2020)

Molecular basis for multimerization in the activation of the epidermal growth factor receptor
por: Huang, Yongjian, et al.
Publicado: (2016)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib
por: Tang, Ping, et al.
Publicado: (2022)

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
por: Sasada, Tetsuro, et al.
Publicado: (2016)

Ip-10 Inhibits Epidermal Growth Factor–Induced Motility by Decreasing Epidermal Growth Factor Receptor–Mediated Calpain Activity
por: Shiraha, Hidenori, et al.
Publicado: (1999)

Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor‐4 inhibition in hepatocellular carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2022)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor.
por: Mellon, J. K., et al.
Publicado: (1996)

Expression and localization of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in the canine testis
por: TAMADA, Hiromichi, et al.
Publicado: (2015)

Napsin A and Thyroid Transcription Factor-1-Positive Cerebellar Tumor with Epidermal Growth Factor Receptor Mutation
por: Kuwata, Taiji, et al.
Publicado: (2011)

The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer
por: Gong, Zhongqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qnli7pvb8hhlpgjs9h2jfjcbgq